Deutsche Bank Reiterates Buy on Achillion Pharmaceuticals (ACHN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
FBR Capital Says Achillion's (ACHN) Nuc Has Greatest Potency Versus Gilead's (GILD) Sovaldi in the GT3 HCV Subtype
October 1, 2014 1:06 PM EDTFBR Capital analyst Andrew Beren offered some positive comments on Achillion Pharmaceuticals (NASDAQ: ACHN) moments ago noting abstracts from AASLD showcasing preclinical data for Achillions ACH-3422 suggest that the NS5B nucleotide (nuc) inhibitor may have the greatest potency versus Gileads Sovaldi in the GT3 HCV subtype (7-fold as potent).
"Importantly, we view the GT3 subtype as the genotype with the greatest unmet medical need currently, as it requires extended duration... More
Achillion Pharma (ACHN), Novavax (NVAX) Lower as Johnson & Johnson Acquires Alios BioPharm.
September 30, 2014 10:14 AM EDTAchillion Pharma (NASDAQ: ACHN) is down 4% early amid investors concern after Johnson & Johnson (NYSE: JNJ) announced a definitive agreement to acquire privately-held Alios BioPharma, not Achillion or Novavax (NASDAQ:... More
